BlackRock (BLK) Prices 28.753M Share Secondary Offering at $420/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures subdued as investors weigh earnings, oil prices
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil prices hit fresh 6-week highs on renewed Middle East tensions
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
PNC Financial Services (PNC) is Said to Sell BlackRock (BLK) Stake at $420 Per Share - Bloomberg
May 12, 2020 5:38 PM EDTPNC Financial Services (NYSE: PNC) is Said to Sell BlackRock (NYSE: BLK) Stake at $420 Per Share - Bloomberg
... MorePre-Open Stock Movers 05/12: (CBAY) (NVAX) (IIVI) Higher; (GNFT) (STRO) (EB) Lower (more...)
May 12, 2020 9:11 AM EDTToday's Pre-Open Stock Movers:
CymaBay Therapeutics (NASDAQ: CBAY) 144.6% HIGHER; independent expert panel unanimously concludes there is no clinical, biochemical or histological evidence of seladelpar-induced liver injury in Phase 2b NASH study.
GENFIT (Nasdaq: GNFT) 50.7% LOWER; announced results from an interim analysis of the RESOLVE-IT Phase 3 trial evaluating once-daily, 120mg of elafibranor in adults with non-alcoholic steatohepatitis (NASH). The trial did not meet the predefined primary endpoint of NASH resolution without worsening of fibrosis in... More
BlackRock throws weight behind new NYSE and Nasdaq challenger MEMX
May 12, 2020 9:01 AM EDTBy John McCrank
NEW YORK (Reuters) - The Members Exchange on Tuesday said BlackRock Inc (NYSE: BLK), the world's biggest asset manager, was among its latest financial and strategic backers as the new bourse gears up to take on the New York Stock Exchange and Nasdaq Inc (NASDAQ: NDAQ) with a third-quarter launch.
MEMX, which was... More
After-Hours Stock Movers 05/11: (CBAY) (YRCW) (NVAX) Higher; (GNFT) (STRO) (EB) Lower (more...)
May 11, 2020 5:53 PM EDTToday's After-Hours Stock Movers:
CymaBay Therapeutics (CBAY) 119% HIGHER; independent expert panel unanimously concludes there is no clinical, biochemical or histological evidence of seladelpar-induced liver injury in Phase 2b NASH study.
GENFIT (Nasdaq: GNFT) 50.7% LOWER; announced results from an interim analysis of the RESOLVE-IT Phase 3 trial evaluating once-daily, 120mg of elafibranor in adults with non-alcoholic steatohepatitis (NASH). The trial did not meet the predefined primary endpoint of NASH resolution without worsening of fibrosis in the ITT population of 1,070 patients. The response rate in... More
BlackRock (BLK) Announces Secondary Offering of Its Common Stock Held by PNC; Plans $1.1 Billion Stock Repurchase
May 11, 2020 4:26 PM EDTBlackRock, Inc. (NYSE: BLK) (the Company) today announced the commencement of a secondary offering of its common stock through which The PNC Financial Services Group, Inc. (NYSE: PNC) intends to exit its full investment in the Company. The shares being offered by PNC will be sold in an underwritten public secondary offering. PNC also expects to grant the underwriters a 30-day option to purchase an... More
